



September 28, 2020

✓ **BSE Limited,**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards launch of Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, by the Company, having received an approval from the U.S. FDA earlier.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**

Encl- : a/a.

## Lupin Launches Atorvastatin Calcium Tablets USP

**Mumbai, Baltimore, September 28, 2020:** Pharma major Lupin Limited (Lupin) announced the launch of Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product will be manufactured at Lupin's Nagpur facility in India.

Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, is the generic equivalent of Lipitor® Tablets, 10 mg, 20 mg, 40 mg and 80 mg, of Pfizer Inc., and indicated to lower cholesterol in blood for adults and children over 10 years of age. Atorvastatin is also prescribed to lower the risk of heart attack and stroke in patients with cardiovascular diseases, diabetes and other risk factors such as eye problems, kidney diseases or high blood pressure.

Atorvastatin Calcium Tablets USP (RLD: Lipitor®) had annual sales of approximately USD 559 million in the U.S. (IQVIA MAT July 2020).

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the 3<sup>rd</sup> largest pharmaceutical company in the U.S. by prescriptions and 5<sup>th</sup> in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on Twitter: [www.twitter.com/LupinGlobal](https://www.twitter.com/LupinGlobal) | LinkedIn: [www.linkedin.com/company/lupin/](https://www.linkedin.com/company/lupin/)

Facebook: [www.facebook.com/LupinWorld/](https://www.facebook.com/LupinWorld/)



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

**For further information or queries please contact –**

**Arvind Bothra**

Head – Investor Relations and Corporate Communications

Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

Tel: +91 22 6640 8237

**Manjira Sharma**

General Manager – Corporate Communications

Email: [manjirasharma@lupin.com](mailto:manjirasharma@lupin.com)

Tel: +91 22 6640 2532

**[\\*Safe Harbor Statement](#)**

Lipitor® is a registered trademark of Pfizer Ireland Pharmaceuticals Corporation